Temasek-backed Advanced MedTech completed the acquisition of a majority stake in WIKKON.

Temasek-backed Advanced MedTech, an integrated urology company, completed the acquisition of a majority stake in WIKKON, the Chinese provider of urology and shock wave therapy devices. Financial terms were not disclosed. "We are now uniquely placed to aggressively grow in China’s sizeable market, which is best served by domestically produced devices. Advanced MedTech’s integrated urology platform is accelerated by WIKKON’s significant R&D, manufacturing, supply chain, and installed base of units. Our newly combined portfolio will allow us to serve urology customers seeking value oriented solutions right through to premium oriented customers globally," Abel Ang, Advanced MedTech CEO.